Siddharth Kaul
Expertise in
14
conditions

Dr. Siddharth Kaul

Neurology
12266 DePaul Drive, Suite 100, 
Bridgeton, MO 
Accepting New Patients
Offers Telehealth
Expertise in
14
conditions
12266 DePaul Drive, Suite 100, 
Bridgeton, MO 

Overview

A board-certified neurologist, Dr. Kaul attended medical school at A.C.P.M. Medical College in India and completed his residency training at Southern Illinois University, Department of Neurology, in Springfield. He has a PhD in neuroscience and has conducted extensive research in the field of Parkinson's disease and movement disorders. Dr. Kaul's experience includes treating stroke, neuropathy, epilepsy, infectious meningitis, migraines and pediatric neurology cases. He is highly proficient in performing electromyography (EMG), reading electroencephalogram (EEG) tracings and performing botox injections for headache and spasticity.

Dr. Kaul is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Migraine, Chediak-Higashi Syndrome, Herpes Simplex Encephalitis, and Sciatica.

Dr. Kaul is board certified in American Board Of Psychiatry & Neurology , Missouri Dept Of Health/Narcotics&Dangerous Drugs , Illinois Department Of Financial & Professional Regulation , Missouri State Board Of Registration, and Drug Enforcement Administration . He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 11 clinical trials. Dr. Kaul is currently accepting new patients.

Specialties

Neurology

Licenses

Hospitalist in FL

Board Certifications

American Board Of Psychiatry & Neurology
Missouri Dept Of Health/Narcotics&Dangerous Drugs
Illinois Department Of Financial & Professional Regulation
Missouri State Board Of Registration
Drug Enforcement Administration

Hospital Affiliations

Adventhealth Orlando
Ssm St Clare Health Center
Ssm St Joseph Health Center
Ssm Health Depaul Hospital St Louis
Ssm St Joseph Hospital West
SSM Health DePaul Hospital - St. Louis
SSM Health St. Clare Hospital - Fenton
SSM Health St. Joseph Hospital - Lake Saint Louis
SSM Health St. Mary's Hospital - St. Louis

Languages Spoken

English
German
Hindi
Marathi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

SSM Health Neurosciences
12266 DePaul Drive, Suite 100, Bridgeton, MO 63044

Additional Areas of Focus

Dr. Kaul has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Spasticity
Movement Disorders

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drugs: Donanemab, Aducanumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 17, 2024
Intervention Type: Drug
Study Drug: AGB101
Study Phase: Phase 2/Phase 3
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: LY3303560
Study Phase: Phase 2
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: July 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

1 Total Publications

Impaired pentagon drawing is an early predictor of cognitive decline in Parkinson's disease.
Impaired pentagon drawing is an early predictor of cognitive decline in Parkinson's disease.
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: June 22, 2013
Similar Doctors
Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Washington University

660 S Euclid Ave, 
Saint Louis, MO 
 (12.2 miles away)
314-454-6120
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Gutmann is a Neurologist practicing medicine in Saint Louis, Missouri. Dr. Gutmann is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Neurofibromatosis, Optic Glioma, Neurofibromatosis Type 1 (NF1), and Glioma. Dr. Gutmann is currently accepting new patients.

Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required

St. Louis Children's Hospital

1 Childrens Pl, 
Saint Louis, MO 
 (12.0 miles away)
314-454-6120
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients

Renee Shellhaas is a Neurologist practicing medicine in Saint Louis, Missouri. Dr. Shellhaas is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Epilepsy in Children, West Syndrome, Spasmus Nutans, and Seizures. Dr. Shellhaas is currently accepting new patients.

Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (12.0 miles away)
314-747-1171
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Milan Chheda is a Neurologist practicing medicine in Saint Louis, Missouri. Dr. Chheda is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, and Brain Tumor. Dr. Chheda is currently accepting new patients.

Frequently Asked Questions about Dr. Siddharth Kaul

How do I make an appointment with Dr. Siddharth Kaul?

You can book an appointment with Dr. Siddharth Kaul by calling their office at 314-738-2770. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Siddharth Kaul a top-rated expert for Migraine?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Siddharth Kaul is classified as an Distinguished expert for Migraine, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Siddharth Kaul specialize in?

While Dr. Siddharth Kaul is a Neurology, they have specific expertise in Migraine, Chediak-Higashi Syndrome, and Herpes Simplex Encephalitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Siddharth Kaul participate in research or clinical trials?

Yes. Dr. Siddharth Kaul has published 1 articles and abstracts on conditions like Migraine. You can view a list of Dr. Siddharth Kaul's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Siddharth Kaul accept my insurance?

Dr. Siddharth Kaul accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 314-738-2770 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kaul's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 66 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile